To include your compound in the COVID-19 Resource Center, submit it here.

Carfilzomib: Phase II data

Data from 50 evaluable patients in the Phase II portion of the open-label, dose-escalation, North American Phase Ib/II PX-171-006 trial showed that 27 mg/m 2

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE